Lantheus Holdings (LNTH) Stock Analysis & Winston Score

Lantheus Holdings makes specialized medical imaging agents — substances injected into patients so doctors can see inside the body more clearly using scans. Its most important product is PYLARIFY, a radioactive tracer used to detect prostate cancer using a type of scan called a PET scan. Hospitals, cancer centers, and nuclear medicine facilities across the United States are its main customers. The company earns money by selling these imaging agents directly to healthcare providers, with PYLARIFY driving the large majority of its revenue. Lantheus operates primarily in the United States, where it holds a leading position in prostate cancer imaging. Its moat comes from the technical complexity of making radioactive drugs, which require specialized manufacturing and strict regulatory approvals that are hard for competitors to replicate quickly. The key growth driver is expanding use of PET imaging in oncology, but the main risk is competition from rival tracers and potential pricing pressure from large hospital networks.